{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:08:08Z","timestamp":1780931288519,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Newly diagnosed immune thrombocytopenia is typically transient, with severe bleeding rarely occurring despite low platelet counts. In the absence of significant bleeding, observation without treatment is considered safe in children. Despite guidelines prioritizing bleeding scores over platelet counts to guide treatment decisions, this practice is not widely adopted. The safety and benefit of modifying local practices to follow these guidelines remain unclear. The objective was to describe treatment and hospitalization rates after guideline implementation and to assess the occurrence of complications and persistent immune thrombocytopenia in the POST group compared with the PRE group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The new algorithm recommended treatment for patients with Buchanan score \u22653 regardless of platelet count, while the previous one suggested treatment if platelet count &amp;lt;10 \u00d7 109\/L. We compared patient management before (PRE: January 2019\u2013December 2020) and after (POST: January 2022\u2013December 2023) implementation of new local guidelines in the paediatric emergency department of Hospital Sainte-Justine, Quebec.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 84 patients: 34 PRE and 50 POST with comparable characteristics. In the POST period, the guideline was followed in 88% of the cases, more patients were observed without treatment (PRE 24%, POST 58% P = 0.002) and less were hospitalized at diagnosis (PRE 62%, POST 22% P = 0.0005). The effect was mainly due to a higher observation rate in patients with low bleeding score (PRE 32%, POST 84%). No intracranial bleeding, death, or increased persistent ITP rate was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In sum, transitioning from platelet-based to bleeding score based guidelines was safe, reduced treatment use in the emergency department, and decreased hospitalizations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pch\/pxaf126","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:07:59Z","timestamp":1764940079000},"page":"333-339","source":"Crossref","is-referenced-by-count":0,"title":["Improvement of newly diagnosed immune thrombocytopenia management in children by implementing revised practice guidelines"],"prefix":"10.1093","volume":"31","author":[{"given":"Cl\u00e9o","family":"Hautefeuille","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Cot\u00e9","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, CHU Sainte-Justine , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Parisien","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, CHU Sainte-Justine , Montreal, Quebec ,","place":["Canada"]},{"name":"Department of Pediatrics, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"D. Trottier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec ,","place":["Canada"]},{"name":"Department of Emergency Medicine, CHU Sainte-Justine , Montreal, Quebec ,","place":["Canada"]},{"name":"CHU Sainte-Justine Azrieli Research Center , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves D","family":"Pastore","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine , Montreal, Quebec ,","place":["Canada"]},{"name":"Department of Pediatrics, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec ,","place":["Canada"]},{"name":"CHU Sainte-Justine Azrieli Research Center , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pincez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine , Montreal, Quebec ,","place":["Canada"]},{"name":"Department of Pediatrics, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec ,","place":["Canada"]},{"name":"CHU Sainte-Justine Azrieli Research Center , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"14","key":"2026060810565695400_pxaf126-B1","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1182\/blood-2012-07-442392","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: Report from the International Working Group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026060810565695400_pxaf126-B2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"issue":"7","key":"2026060810565695400_pxaf126-B3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/pbc.25961","article-title":"Multicenter cohort study comparing U.S. management of inpatient pediatric immune thrombocytopenia to current treatment guidelines","volume":"63","author":"Witmer","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026060810565695400_pxaf126-B4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1365-2141.2010.08176.x","article-title":"Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database","volume":"149","author":"Yong","year":"2010","journal-title":"Br J Haematol"},{"issue":"22","key":"2026060810565695400_pxaf126-B5","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","article-title":"Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group (ICIS)","volume":"121","author":"Neunert","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2026060810565695400_pxaf126-B6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1067\/S0022-3476(03)00535-3","article-title":"A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group\u2217","volume":"143","author":"K\u00fchne","year":"2003","journal-title":"J Pediatr"},{"issue":"1","key":"2026060810565695400_pxaf126-B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.16751","article-title":"Fatigue in children and adolescents with immune thrombocytopenia","volume":"191","author":"Grace","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2026060810565695400_pxaf126-B8","doi-asserted-by":"publisher","first-page":"e26405","DOI":"10.1002\/pbc.26405","article-title":"Patterns and influences in health-related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP cohort","volume":"64","author":"Flores","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026060810565695400_pxaf126-B9","doi-asserted-by":"publisher","first-page":"e29023","DOI":"10.1002\/pbc.29023","article-title":"Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia","volume":"68","author":"Shimano","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"2026060810565695400_pxaf126-B10","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: Pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2026060810565695400_pxaf126-B11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: A systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026060810565695400_pxaf126-B12","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2008-03-138487","article-title":"Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura","volume":"112","author":"Neunert","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2026060810565695400_pxaf126-B13","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1182\/bloodadvances.2024015494","article-title":"Critical bleeding in adults and children with immune thrombocytopenia: A multicenter cohort study","volume":"9","author":"Sirotich","year":"2025","journal-title":"Blood Adv"},{"issue":"23","key":"2026060810565695400_pxaf126-B14","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2026060810565695400_pxaf126-B15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1067\/mpd.2002.128547","article-title":"Grading of hemorrhage in children with idiopathic thrombocytopenic purpura","volume":"141","author":"Buchanan","year":"2002","journal-title":"J Pediatr"},{"issue":"16","key":"2026060810565695400_pxaf126-B16","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2026060810565695400_pxaf126-B17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060810565695400_pxaf126-B18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/pch\/pxy197","article-title":"Diagnosis and management of typical, newly diagnosed primary immune thrombocytopenia (ITP) of childhood","volume":"24","author":"Friedman","year":"2019","journal-title":"Paediatr Child Health"},{"issue":"5","key":"2026060810565695400_pxaf126-B19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1542\/peds.2012-2021","article-title":"Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children's hospitals","volume":"131","author":"Kime","year":"2013","journal-title":"Pediatrics"},{"key":"2026060810565695400_pxaf126-B20","author":"Expert Panel on immune globulin product supply and related impacts in Canada"},{"issue":"13","key":"2026060810565695400_pxaf126-B21","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia","volume":"8","author":"Neunert","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026060810565695400_pxaf126-B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/adc.2010.184234","article-title":"Changing trends in the UK management of childhood ITP","volume":"97","author":"Grainger","year":"2012","journal-title":"Arch Dis Child"},{"key":"2026060810565695400_pxaf126-B23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpeds.2022.11.036","article-title":"Cost-effectiveness of a quality improvement initiative for the clinical management of children with newly diagnosed immune thrombocytopenia","volume":"256","author":"Moskalewicz","year":"2023","journal-title":"J Pediatr"},{"issue":"11","key":"2026060810565695400_pxaf126-B24","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2026060810565695400_pxaf126-B25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13223-023-00841-z","article-title":"Immunoglobulin utilization in Canada: A comparative analysis of provincial guidelines and a scoping review of the literature","volume":"19","author":"Harmon","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"12","key":"2026060810565695400_pxaf126-B26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1111\/trf.18031","article-title":"The impact of institutional measures on optimal use of intravenous immunoglobulin","volume":"64","author":"Champagne","year":"2024","journal-title":"Transfusion (Paris)"},{"issue":"3","key":"2026060810565695400_pxaf126-B27","first-page":"376","article-title":"A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura","volume":"72","author":"Fujisawa","year":"2000","journal-title":"Int J Hematol"},{"issue":"6","key":"2026060810565695400_pxaf126-B28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/s0022-3476(05)80400-7","article-title":"A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura","volume":"123","author":"Blanchette","year":"1993","journal-title":"J Pediatr"},{"issue":"8924","key":"2026060810565695400_pxaf126-B29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/s0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet Lond Engl"},{"issue":"8453","key":"2026060810565695400_pxaf126-B30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s0140-6736(85)90400-3","article-title":"Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood","volume":"2","author":"Imbach","year":"1985","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"2026060810565695400_pxaf126-B31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.clinthera.2009.05.006","article-title":"Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura","volume":"31","author":"Xie","year":"2009","journal-title":"Clin Ther"},{"issue":"3","key":"2026060810565695400_pxaf126-B32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/(sici)1096-8652(200003)63:3%3C156::aid-ajh9%3E3.0.co;2-4","article-title":"The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin","volume":"63","author":"Sandler","year":"2000","journal-title":"Am J Hematol"},{"issue":"3","key":"2026060810565695400_pxaf126-B33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2450\/BloodTransfus.501","article-title":"Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology","volume":"22","author":"Russo","year":"2024","journal-title":"Blood Transfus Trasfus Sangue"},{"issue":"9","key":"2026060810565695400_pxaf126-B34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: A randomized controlled trial","volume":"132","author":"Heitink-Poll\u00e9","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026060810565695400_pxaf126-B35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/MPH.0b013e3182329b4f","article-title":"Analysis of health-related quality of life in children with immune thrombocytopenia and their parents using the kids' ITP tools","volume":"34","author":"Zilber","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2026060810565695400_pxaf126-B36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2026060810565695400_pxaf126-B37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate Mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2026060810565695400_pxaf126-B38","doi-asserted-by":"publisher","first-page":"e30074","DOI":"10.1002\/pbc.30074","article-title":"Utilization of an ITP quality improvement pathway improves adherence to management guidelines","volume":"70","author":"Harris","year":"2023","journal-title":"Pediatr Blood Cancer"}],"container-title":["Paediatrics &amp; Child Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pch\/article-pdf\/31\/4\/333\/67339890\/pxaf126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pch\/article-pdf\/31\/4\/333\/67339890\/pxaf126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:57:02Z","timestamp":1780930622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pch\/article\/31\/4\/333\/8519343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/pch\/pxaf126","relation":{},"ISSN":["1205-7088","1918-1485"],"issn-type":[{"value":"1205-7088","type":"print"},{"value":"1918-1485","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,13]]}}}